The FirstTake - FirstWord's editors discuss the latest pharma news and offer insights from industry experts and KOLs. Designed for the busy pharma industry professional. Visit us at beta.firstwordpharma.com to sign up for newsletters delivering timely news and event-driven physician intelligence.
The FirstTake Podcast – 16 September 2021
In this episode editors Virginia Li, Michael Flanagan and Simon King discuss AbbVie’s deal to in-license an investigational gene therapy for age related macular degeneration from Regenxbio, an increasing focus on mRNA vaccines and therapeutics among Chinese biotech companies and why a new academic study may pose further challenges for Biogen’s Aduhelm.
The FirstTake Podcast – Sanofi’s M&A hunt continues
In this episode, editors Michael Flanagan and Simon King discuss Sanofi’s latest acquisition, ongoing safety concerns around gene therapies and expert feedback on anti-Tau therapies for Alzheimer’s disease.
The FirstTake Podcast – JAKs, Jardiance and booster shots
In this episode editors Michael Flanagan and Simon King the FDA’s new safety labelling for JAK inhibitors, impressive new data for Jardiance in heart failure and controversy around COVID-19 booster shots.
The FirstTake Podcast – A landmark approval in lupus
This week FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss US approval of the first new lupus therapy in a decade, Eli Lilly’s optimistic body language about bringing a new Alzheimer’s disease treatment to market next year and Sanofi’s acquisition of messenger RNA specialist Translate Bio.
The FirstTake Podcast – A tale of two COVID-19 vaccines
FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss Pfizer’s projected COVID-19 vaccine revenues for 2021 and whether clinical data validates the commercial dominance of this product over AstraZeneca’s competing vaccine, look at Keytruda’s increasingly compelling profile as a treatment for early-stage and advanced triple-negative breast cancer (TNBC) and put Amgen’s acquisition of Teneobio under the spotlight.
The FirstTake Podcast – Q2 earnings kick off with yet more Aduhelm controversy
FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the start of Q2 earnings season, including the receding impact of COVID-19 on drug sales and Biogen’s claim of a misinformation conspiracy designed to derail adoption of Aduhelm. Also under the spotlight is the HIF-PH drug class and new cardiovascular data from Cytokinetics.